1
2
#OpenInnovation
3
4
News & Events
Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate
December 2, 2020
Exelixis now has responsibility for Tissue Factor (TF)-targeting ADC now known as XB002 (formerly ICON-2). Read more
FDA Requests More Data to Support LIQ861's Potential Approval for PAH
November 30, 2020
The FDA determined that additional data is required to support the potential approval of LIQ861 for the treatment of pulmonary arterial hypertension. Read more
Imago Biosciences Raises $80 Million In Series C Financing
November 17, 2020
Imago will use the proceeds to complete a Phase 3 study of bomedemstat. Read more
5
#knowledgebase
6
7
News & Events
Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate
December 2, 2020
Exelixis now has responsibility for Tissue Factor (TF)-targeting ADC now known as XB002 (formerly ICON-2). Read more
FDA Requests More Data to Support LIQ861's Potential Approval for PAH
November 30, 2020
The FDA determined that additional data is required to support the potential approval of LIQ861 for the treatment of pulmonary arterial hypertension. Read more
Imago Biosciences Raises $80 Million In Series C Financing
November 17, 2020
Imago will use the proceeds to complete a Phase 3 study of bomedemstat. Read more
8
Portfolio Highlights
#PharmaBiotech
11
Our View
10
Our Focus
12
#PRI
22
Medical Technologies
#Portfolio
14
The fight continues,
we remain vigilant.
#NewNormal
#BreakTheChain
#FlattenTheCurve
16
Words from
the CEO
17
Portfolio Highlights
#PharmaBiotech
28
Pharmaceutical Biotech
#Portfolio
15
About Us
34
Biorenewables & Others
#Portfolio
19
WHAT'S TRENDING @ XERAYA
Exelixis In-Licenses Iconic's TF-Targeting ADC
20
Our Team
21
23
Portfolio Highlights
#Biorenewables
30
Portfolio Highlights
#MedTech
25
26
ARE YOU
The Next
Big Thing?
Submit
A
Proposal
29
36
Career
#Xeraya
35
37
News & Events
Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate
December 2, 2020
Exelixis now has responsibility for Tissue Factor (TF)-targeting ADC now known as XB002 (formerly ICON-2). Read more
FDA Requests More Data to Support LIQ861's Potential Approval for PAH
November 30, 2020
The FDA determined that additional data is required to support the potential approval of LIQ861 for the treatment of pulmonary arterial hypertension. Read more
Imago Biosciences Raises $80 Million In Series C Financing
November 17, 2020
Imago will use the proceeds to complete a Phase 3 study of bomedemstat. Read more
32
#agro
33
Portfolio Highlights
#Biorenewables
38
Portfolio Highlights
#MedTech
39
40
Contact Us
41
